Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
MDVN acquired the university's MDVN 300 series of small molecule androgen receptor antagonists. MDVN plans to start clinical development of compounds to treat hormone-refractory prostate cancer (HRPC...
